In the battle against AML, the effect of PI3K/AKT/mTOR inhibition can be augmented by BCL-2, which is an anti-apoptotic protein often overexpressed in several blood disorders, including AML. This evidence concerns the gene BCL2 and acute myeloid leukemia.